Figure 1 | Hypertension Research

Figure 1

From: Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial

Figure 1

Principal safety outcomes in the safety population in the on-treatment analysis according to hypertensive status. (a) Principal safety outcomes in patients with and without hypertension. (b) Kaplan–Meier curve of time to first major bleeding event or first non-major clinically relevant bleeding event. CI, confidence interval; HR, hazard ratio; N/A, not applicable.

Back to article page